
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5416433/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy of Gabapentin in Migraine Prophylaxis. Headache, 2001, 41, 119-128.	3.9	317
2	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1081-1090.	10.2	236
3	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1091-1100.	10.2	221
4	Analgesic Rebound Headache in Clinical Practice: Data From a Physician Survey. Headache, 1996, 36, 14-19.	3.9	143
5	Obesity and Migraine: The Effect of Age, Gender and Adipose Tissue Distribution. Headache, 2010, 50, 52-62.	3.9	130
6	Calcitonin Geneâ€Related Peptide (<scp>CGRP</scp>) and Migraine Current Understanding and State of Development. Headache, 2013, 53, 1230-1244.	3.9	128
7	Analgesic Rebound Headache. Headache, 1988, 28, 662-665.	3.9	119
8	Medications Associated with Probable Medication Overuse Headache Reported in a Tertiary Care Headache Center Over a 15-Year Period. CME. Headache, 2006, 46, 766-772.	3.9	118
9	Intranasal Civamide for the Treatment of Episodic Cluster Headaches. Archives of Neurology, 2002, 59, 990.	4.5	110
10	Triptans for the Management of Migraine. Drugs, 2010, 70, 1505-1518.	10.9	110
11	Memantine in the Preventive Treatment of Refractory Migraine. Headache, 2008, 48, 1337-1342.	3.9	88
12	New strategies for the treatment and prevention of primary headache disorders. Nature Reviews Neurology, 2016, 12, 635-650.	10.1	83
13	Satisfaction With Current Migraine Therapy: Experience From 3 Centers in US and Sweden. Headache, 2007, 47, 475-479.	3.9	82
14	The Triptan Formulations. CNS Drugs, 2003, 17, 431-447.	5.9	74
15	Intranasal Medications for the Treatment of Migraine and Cluster Headache. CNS Drugs, 2004, 18, 671-685.	5.9	62
16	The Impact of Topiramate on Healthâ€Related Quality of Life Indicators in Chronic Migraine. Headache, 2007, 47, 1398-1408.	3.9	57
17	Innovative Delivery Systems for Migraine. CNS Drugs, 2010, 24, 929-940.	5.9	46
18	Triptans Are All Different. Archives of Neurology, 2001, 58, 1479.	4.5	39

#	Article	IF	CITATIONS
19	Role of Antiepileptic Drugs as Preventive Agents for Migraine. CNS Drugs, 2010, 24, 21-33.	5.9	39
20	Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. Journal of Headache and Pain, 2019, 20, 83.	6.0	37
21	Obesity and Chronic Daily Headache. Current Pain and Headache Reports, 2012, 16, 101-109.	2.9	33
22	Update on the Pharmacological Treatment of Chronic Migraine. Current Pain and Headache Reports, 2016, 20, 6.	2.9	32
23	The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Postâ€Hoc Analyses on the First 3 Weeks of Treatment. Headache, 2019, 59, 383-393.	3.9	32
24	DFNâ€02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Doubleâ€Blind, Placebo ontrolled Study. Headache, 2018, 58, 676-687.	3.9	31
25	The Association of Obesity With Episodic and Chronic Migraine. Headache, 2012, 52, 663-671.	3.9	29
26	Medication Overuse Headache. CNS Drugs, 2008, 22, 995-1004.	5.9	28
27	Naratriptan in the Preventive Treatment of Refractory Chronic Migraine: A Review of 27 Cases. Headache, 2003, 43, 482-489.	3.9	27
28	Levetiracetam in the preventive treatmentof transformed migraine: A prospective, open-label, pilot study. Current Therapeutic Research, 2005, 66, 212-221.	1.2	26
29	The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update. CNS Drugs, 2021, 35, 545-565.	5.9	25
30	Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatric Disease and Treatment, 2012, 8, 429.	2.2	23
31	The therapeutic future in headache. Neurological Sciences, 2012, 33, 119-125.	1.9	23
32	Migraine and episodic Vertigo: a cohort survey study of their relationship. Journal of Headache and Pain, 2019, 20, 33.	6.0	23
33	Prophylactic migraine therapy: Emerging treatment options. Current Pain and Headache Reports, 2004, 8, 178-184.	2.9	21
34	A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10Amg plus permeation enhancer DDM, for the acute treatment of episodic migraine. Journal of Headache and Pain, 2017, 18, 31.	6.0	17
35	Acute and prophylactic treatments for migraine: present and future. Neurological Sciences, 2008, 29, 110-122.	1.9	16
36	The Pipeline in Headache Therapy. CNS Drugs, 2013, 27, 717-729.	5.9	16

#	Article	IF	CITATIONS
37	Device profile of the Nerivioâ,,¢ for acute migraine treatment: overview of its efficacy and safety. Expert Review of Medical Devices, 2019, 16, 1017-1023.	2.8	16
38	Naratriptan in the Preventive Treatment of Refractory Transformed Migraine: A Prospective Pilot Study. Headache, 2005, 45, 1400-1406.	3.9	15
39	New acute treatments for headache. Neurological Sciences, 2010, 31, 129-132.	1.9	15
40	Emerging treatments for the primary headache disorders. Neurological Sciences, 2015, 36, 109-113.	1.9	14
41	Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine. Headache, 2020, 60, 229-234.	3.9	14
42	Neurobiology of migraine progression. Neurobiology of Pain (Cambridge, Mass), 2022, 12, 100094.	2.5	14
43	New developments in migraine prophylaxis. Expert Opinion on Pharmacotherapy, 2003, 4, 433-443.	1.8	13
44	New treatments for headache. Neurological Sciences, 2014, 35, 89-97.	1.9	13
45	A new era in headache treatment. Neurological Sciences, 2018, 39, 47-58.	1.9	13
46	What Happens to the Old Headache Medicines?. Headache, 2012, 52, 701-706.	3.9	11
47	Scent of aura? Clinical features of olfactory hallucinations during a migraine attack (OHM). Cephalalgia, 2017, 37, 154-160.	3.9	10
48	Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Pain Management, 2014, 4, 123-128.	1.5	9
49	Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache. Neurological Sciences, 2019, 40, 75-80.	1.9	9
50	Acute treatment of migraine headache. Techniques in Regional Anesthesia and Pain Management, 2009, 13, 9-15.	0.2	8
51	Acute and preventive treatment of cluster headache and other trigeminal autonomic cephalgias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 431-442.	1.8	8
52	Acute Treatment of Migraine: Established and Emerging Therapies. Headache, 2012, 52, 60-64.	3.9	8
53	Diclofenac potassium for oral solution (CAMBIA [®]) in the acute management of a migraine attack: clinical evidence and practical experience. Therapeutic Advances in Neurological Disorders, 2017, 10, 217-226.	3.5	7
54	Acute Care and Treatment of Migraine. Journal of Neuro-Ophthalmology, 2020, 40, 472-484.	0.8	7

#	Article	IF	CITATIONS
55	Update on future headache treatments. Neurological Sciences, 2013, 34, 101-108.	1.9	5
56	Potassium channel openers — novel triggers of aura and migraine. Nature Reviews Neurology, 2021, 17, 397-398.	10.1	5
57	New drug delivery options for migraine. Expert Review of Neurotherapeutics, 2011, 11, 771-773.	2.8	4
58	Frovatriptan: Pharmacological Differences and Clinical Results. Current Medical Research and Opinion, 2001, 17, s68-70.	1.9	3
59	The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective. Therapeutic Advances in Neurological Disorders, 2015, 8, 160-165.	3.5	3
60	The Authors' Reply. CNS Drugs, 2011, 25, 171-173.	5.9	1
61	Commentary on Westergaard's "Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review― Cephalalgia, 2015, 35, 637-638.	3.9	0
62	The Headache Cooperative of New England (HCNE) Symposium on Calcitonin Geneâ€Related Peptide. Headache, 2018, 58, 217-217.	3.9	0